MASM
DFTX

MH & Associates Securities Management’s Definium Therapeutics DFTX Stock Holding History

MH & Associates Securities Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1K Hold
66
– – ﹤0.01% 86
2026
Q1 		$1.25K Hold
66
– – ﹤0.01% 90
2025
Q4 		$884 Buy
+66
New +$817 ﹤0.01% 98

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

MH & Associates Securities Management's DFTX Position: Q2 2026 in Review

MH & Associates Securities Management held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 66 shares worth $3.1K. The position accounts for ﹤0.01% of the portfolio, ranked #86.

MH & Associates Securities Management first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • MH & Associates Securities Management held 66 shares of Definium Therapeutics worth $3.1K as of Q2 2026.
  • MH & Associates Securities Management left its Definium Therapeutics share count unchanged in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of MH & Associates Securities Management's portfolio in Q2 2026, its #86 holding.
  • MH & Associates Securities Management first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on MH & Associates Securities Management's 13F filing for Q2 2026, filed 28 Jul 2026.